



## The National Agricultural Development Company Investors Presentation

### Disclaimer



The content in this presentation may change at any time, its correctness cannot be guaranteed, and it might not include all relevant information about the Company. We do not guarantee the accuracy or completeness of any information given herein and do not accept liability or responsibility for any error or omission.

The data also includes forecasts and forward-looking statements that represent the Company's current perspectives on upcoming developments and financial performance. These opinions are founded on current presumptions, which have several risks and could evolve over time. The occurrence of future events, the realization of projections, or the accuracy of the Company's assumptions cannot be guaranteed. Real outcomes could be much different from those anticipated.

Under no circumstances may this presentation be distributed without NADEC's express permission.









## Dr.Solaiman A.AlTwaijri

**Chief Executive Officer** 



## Hassan Aqrouq

**Vice President - Finance** 








#### Outlook

#### **Financial Performance**

#### Appendix


Private and Confidential





#### Outlook





## Today, NADEC is a leading dairy, juice and agri player








- #6 Most Influential Local Brand in KSA (IPSOS, 2022)
- Recognized by SFDA, amongst top 5 companies in KSA, for providing healthier food solutions in the region (e.g., reduction of sugar and salt)



## Overall, NADEC aims to more than double its revenues and become a SAR 6.0 Bn company





## Moving forward, NADEC will transform into a total food company



# TARGET **Total Food Company Total Food** Company

Expand production, distribution and portfolio to solidify NADEC's position in **Dairy and Juice** and deliver sustainable profitable growth

02

Work with local farmers to provide a **large basket of high-quality produce** to consumers


03

Enter the **Red Meat** sector to provide high-quality, ready-to-cook products to consumers


#### Nadec Market Share (in %)



#### **Volume Share**







#### **Financial Performance**


## **Financial Highlights**




30.0%

6.1%


3.5%






**Balance Sheet** 










Private and Confidential

## Net Income Bridge






\*Others includes the one-off items i.e. Write off/ Impairment losses on Property, Plant and Equipment and Capital work in progress.

Private and Confidential

CVD	Million
SAR	IVIIIION









## Net Debt and EBITDA/ EBIT Margins Trend




SAR Million






## Debt Maturity Profile – Average debt tenure at 2.5 Years









#### Appendix

## **Income Statement**



SAR million		
Income Statement	FY22	FY21
Revenue from Operations	2,694	2,272
Cost of Good Sold	1,886	1,641
Gross Profit	808	631
Selling General & Admin Exp.	632	637
Other Operating Expenses*	30	207
EBITDA	375	50
Depreciation	228	264
Operating Profit	147	(213)
Finance Cost	49	32
Share of Profit in JV	3	0
PBT	101	(245)
Zakat	6	40
Net Income	95	(285)

\*Other operating expenses includes Provision for Bad Debts; R&D Expenses; Other Operating expenses; Provision and Write-offs

## **Summarized Balance Sheet**



SAR million			
Balance Sheet	Dec 31, 2022	Dec 31, 2021	
Non-Current Assets	2,707	2,745	
Current Assets	1,115	1,145	
Total Assets	3,822	3,890	
Non-Current Liabilities	1,090	1,364	
Current Liabilities	1,437	1,330	
Total Liabilities	2,527	2,694	
Shareholders' Equity	1,295	1,196	
Total Shareholders' Equity and Liabilities	3,822	3,890	

## **Cash Flow Statement**



SAR million		
Cash Flow Statement	Dec 31, 2022	Dec 31, 2021
Net Profit/ (Loss)	95	-285
Adjustment for Non-Cash and Non-operating Items	382	610
Cash Operating Profit	477	325
Changes in working capital	(1)	(41)
Zakat Paid	(1)	(1)
Employee Benefits Paid	-23	(28)
Cash Flow from Operating Activities	452	256
Acquisition of PPE, Intangible and Biological Assets	(304)	(362)
Proceeds from sale of PPE and Biological Assets	61	88
Investment in Equity	0	(51)
Cash Flow from Investing Activities	(243)	(325)
Proceeds from Loans and Borrowings	146	370
Repayment of Loans and Borrowings	(264)	(223)
Other Cashflow from financiang activities	(59)	(65)
Cash Flow from Financing Activities	(178)	82
Net Change in Cash and Cash Equivalents	31	13



# Thank you

